Safe Threshold to Discontinue Phototherapy in Hemolytic Disease of Newborn
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age1-14
SponsorMinistry of Health, Saudi Arabia
We hypothesized that adopting a lower rather than a higher threshold for phototherapy discontinuation will be associated with reduced rates of rebound hyperbilirubinemia in term and late preterm neonates with hemolytic disease of newborn.
Objectives: The investigators aimed to compare the safety of implementing low-threshold, compared to high- threshold, of TSB for phototherapy interruption in term and late preterm neonates with hemolytic disease of newborn.
positive DAT and blood group iso-immunization (ABO / RH incompatibility);and /or
HGB decline by 2g/dl within 24hour.
Major congenital abnormalities,
Surgical problems,
Direct hyperbilirubinemia
Sepsis